Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...

4 The most effective application of immunotherapy for the treatment of human cancer is the administration of autologous lymphocytes with reactivity to tumor antigens. New approaches to cell ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO.

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study, published ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with ...

Analysis: Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses ... that PMB-treated mice exhibited reduced infiltration of interferon-gamma (IFN-γ ...

Immunotherapy has revolutionized the management of cancer, including liver malignancies ... This effect is associated with increased infiltration and activation of cytotoxic T lymphocytes and ...

He was enrolled in a clinical trial for immunotherapy — a type of treatment that uses the patient's own immune system to fight cancer — that began in October 2013. Lung cancer poses a larger ...

Driving Innovation of Cancer Immunotherapy BOT has demonstrated ... enhancing T-cell infiltration and antitumor responses in preclinical models. These findings provide a strong rationale for ...

ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the ...

ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...